Sparks - BB Biotech

BB Biotech has announced its preliminary FY25 results. The company delivered a strong total return of +34.21% (Swiss franc terms), or +37.0% (euro terms), or +53.7% (US dollar terms); this includes the CHF1.80 dividend paid in March 2025. This compares favourably to the +33.4% (US dollar terms) for the benchmark, the Nasdaq Biotechnology Index (NBI), resulting in a share price outperformance of +20.3%. NAV performance amounted to +26.5% (CHF), or +27.8% (€), or +44.8% (US$) for  FY25, versus +3.0% (CHF), or +1.7% (€), or -4.6% (US$) for FY24.

More specifically, in the prior quarter, BB Biotech delivered a robust total return of +24.0% (CHF), or +26.1% (€), or +24.6% (US$), outperforming the NBI, which gained +17.1% (US$) over Q425. NAV performance for the quarter amounted to +20.4% (CHF), or +21.0% (€), or +21.0% (US$).

Encouragingly, BB Biotech ended the year with a narrower discount to NAV (CHF terms) of 10.8%, versus a 15.2% discount at the end of the prior year.

A regular dividend of CHF2.25 per share is being proposed, reflecting a 5% yield based on the average December 2025 share price, consistent with the dividend policy adopted in 2013, reflecting the company’s disciplined approach to balance shareholder returns with reinvestment into long-term growth opportunities.

A review of BB Biotech’s portfolio, full 2025 results and  an outlook for 2026, will be included in the annual report (due to be published on 20 February 2026).